Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- OTC NEWS IN BRIEF
June 27, 2005
- 20 New Kit Products Added to NHI Price List
June 27, 2005
- Half of Glaucoma Patients Lack Subjective Symptoms: Survey
June 27, 2005
- FPMAJ Announces Its 2005 Report on NHI Pricing
June 27, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 27, 2005
- Gov't Approves 2005 White Paper on Aging Society
June 27, 2005
- MEDICAL DEVICE NEWS IN BRIEF
June 27, 2005
- Generic Substitution Only Speculation at This Point: Mr Futagawa
June 27, 2005
- REGULATORY NEWS IN BRIEF
June 27, 2005
- Chugai to Establish New Strategic Marketing Unit in July
June 27, 2005
- Healthnet to Enter Chinese Market with NDA Support Business
June 27, 2005
- Mattson Jack Group to Strengthen Support in Field of Oncology
June 27, 2005
- Takeda Leads Image Ranking among Clinicians: Nikkei BP Survey
June 27, 2005
- BUSINESS NEWS IN BRIEF
June 27, 2005
- NEW PRODUCTS
June 27, 2005
- Consolidated Sales Up 0.8% for 26 Listed Pharma Companies in FY2004
June 20, 2005
- R&D NEWS IN BRIEF
June 20, 2005
- Non-consolidated Sales of 28 Listed JPMA Companies Up 0.8% to \4,184,156 Mil.
June 20, 2005
- 20% of Hepatitis C Patients Untreated Despite Diagnosis
June 20, 2005
- AstraZeneca, Shionogi Conducting Crestor PMS According to ICH E2E
June 20, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…